Skip to main content
Publications
Herring WL , Gallagher ME, Shah N, Morse KC, Mladsi D , Dong OM , Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States . Pharmacoeconomics. 2024 Apr 29. doi: 10.1007/s40273-024-01385-9
Salis F, Bertuletti S, Bonci T, Caruso M, Scott K, Alcock L, Buckley E, Gazit E, Hansen C, Schwickert L, Aminian K, Becker C, Brown P, Carsin AE , Caulfield B, Chiari L, D'Ascanio I, Del Din S, Eskofier BM, Garcia-Aymerich J, Hausdorff JM, Hume EC, Kirk C, Kluge F, Koch S, Kuederle A, Maetzler W, Mico-Amigo EM, Mueller A, Neatrour I, Paraschiv-Ionescu A, Palmerini L, Yarnall AJ, Rochester L, Sharrack B, Singleton D, Vereijken B, Vogiatzis I, Della Croce U, Mazza C, Cereatti A. A multi-sensor wearable system for the assessment of diseased gait in real-world conditions . Front Bioeng Biotechnol. 2023 Apr 21;11:1143248. doi: 10.3389/fbioe.2023.1143248
Spelman T, Herring WL , Zhang Y, Tempest M, Pearson I , Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom . Pharmacoeconomics. 2022 Mar;40(3):323-39. doi: 10.1007/s40273-021-01106-6.
Mazurek M, Huisman MV, Rothman KJ , Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Lip GYH, GLORIA-AF Investigators. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry . Thromb Haemost. 2017 Dec;117(12):2376-88. doi: 10.1160/TH17-08-0555
Lupo PJ, Robinson JO, Diamond PM, Jamal L, Danysh HE , Blumenthal-Barby J, Lehmann LS, Vassy JL, Christensen KD, Green RC, McGuire AL, MedSeq Project Team. Patients' perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project . Per Med. 2016 Jan 1;13(1):13-20.
Mannila MN, Silveira A, Hawe E , Eriksson P, Aillaud MF, Juhan-Vague I, Yudkin J, Margaglione M, Di Minno G, Mussoni L, Tremoli E, Humphries S, Hamsten A, HIFMECH Study Group. Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of beta-fibrinogen genotype and environmental factors. The HIFMECH Study . Thromb Haemost. 2004 Dec;92(6):1240-9.
Konstantoulas C, Hawe E , Saut N, Yudkin JS, Di Minno G, Margaglione M, Hamsten A, Humphries SE, Juhan-Vague I, Ireland H, HIFMECH Study Group. Common variants in the thrombomodulin gene as a risk for myocardial infarction in the north of Europe (HIFMECH Study) . Thromb Haemost. 2004 Mar;91(3):628-30.
Kelberman D, Hawe E , Luong LA, Mohamed-Ali V, Lundman P, Tornvall P, Aillaud MF, Juhan-Vague I, Yudkin JS, Margaglione M, Di Minno G, Tremoli E, Humphries SE, HIFMECH Study Group. HIFMECH study group. Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study . Thromb Haemost. 2004;92(5):1122-8.